The companies will jointly develop and commercialize DS-1062 worldwide, sharing in the development costs and the profits, but Daiichi Sankyo will maintain exclusive rights in Japan.
Formerly the data analytics division of CTCA, Vidence is supporting an immuno-oncology trial for BMS as it looks to grow its network of hospital partners.
This is the fifth neratinib approval for Puma's licensing partner STA, which is also commercializing the drug in Australia, New Zealand, Singapore, and Brunei.
The data collected could improve understanding of drug efficacy, deliver precision cancer care, guide clinical trial matching, and advance research projects.
